119 related articles for article (PubMed ID: 11413275)
1. Biochemical alterations during medication withdrawal in Parkinson's disease with and without neuroleptic malignant-like syndrome.
Ueda M; Hamamoto M; Nagayama H; Okubo S; Amemiya S; Katayama Y
J Neurol Neurosurg Psychiatry; 2001 Jul; 71(1):111-3. PubMed ID: 11413275
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility to neuroleptic malignant syndrome in Parkinson's disease.
Ueda M; Hamamoto M; Nagayama H; Otsubo K; Nito C; Miyazaki T; Terashi A; Katayama Y
Neurology; 1999 Mar; 52(4):777-81. PubMed ID: 10078727
[TBL] [Abstract][Full Text] [Related]
3. [Clinical course and CSF monoamine metabolism in neuroleptic malignant syndrome--a study of nine typical cases and five mild cases].
Nishijima K; Ishiguro T
Seishin Shinkeigaku Zasshi; 1989; 91(6):429-56. PubMed ID: 2479043
[TBL] [Abstract][Full Text] [Related]
4. Neuroleptic malignant syndrome: a study of CSF monoamine metabolism.
Nisijima K; Ishiguro T
Biol Psychiatry; 1990 Feb; 27(3):280-8. PubMed ID: 1689186
[TBL] [Abstract][Full Text] [Related]
5. Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment.
Stefani A; Pierantozzi M; Olivola E; Galati S; Cerroni R; D'Angelo V; Hainsworth AH; Saviozzi V; Fedele E; Liguori C
Neurochem Int; 2017 May; 105():58-63. PubMed ID: 28108196
[TBL] [Abstract][Full Text] [Related]
6. Does dantrolene influence central dopamine and serotonin metabolism in the neuroleptic malignant syndrome? A retrospective study.
Nisijima K; Ishiguro T
Biol Psychiatry; 1993 Jan; 33(1):45-8. PubMed ID: 7678377
[TBL] [Abstract][Full Text] [Related]
7. Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy.
Keyser DL; Rodnitzky RL
Arch Intern Med; 1991 Apr; 151(4):794-6. PubMed ID: 1672810
[TBL] [Abstract][Full Text] [Related]
8. A neuroleptic malignant-like syndrome (NMLS) in a patient with Parkinson's disease resolved with rotigotine: a case report.
Fiore S; Persichino L; Anticoli S; De Pandis MF
Acta Biomed; 2014 Dec; 85(3):281-4. PubMed ID: 25567468
[TBL] [Abstract][Full Text] [Related]
9. Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease.
Cheng FC; Kuo JS; Chia LG; Dryhurst G
J Neural Transm (Vienna); 1996; 103(4):433-46. PubMed ID: 9617787
[TBL] [Abstract][Full Text] [Related]
10. A Fatal Case of Neuroleptic Malignant Syndrome After Paralytic Bowel in a Patient Taking Antiparkinson Medication.
Campa D; Ariello M; Castaldo R; Zibella F; Ferrazza P; Del Gaudio S
Eur J Case Rep Intern Med; 2016; 3(4):000368. PubMed ID: 30755870
[TBL] [Abstract][Full Text] [Related]
11. Neuroleptic malignant syndrome in parkinsonian patients: risk factors.
Kuno S; Mizuta E; Yamasaki S
Eur Neurol; 1997; 38 Suppl 2():56-9. PubMed ID: 9387804
[TBL] [Abstract][Full Text] [Related]
12. Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease.
Poceta JS; Parsons L; Engelland S; Kripke DF
Sleep Med; 2009 Jan; 10(1):129-33. PubMed ID: 18207455
[TBL] [Abstract][Full Text] [Related]
13. Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment.
Bagdy G; Perényi A; Frecska E; Révai K; Papp Z; Fekete MI; Arató M
Psychopharmacology (Berl); 1985; 85(1):62-4. PubMed ID: 2580329
[TBL] [Abstract][Full Text] [Related]
14. It was not just a heatwave! Neuroleptic malignant-like syndrome in a patient with Parkinson's disease.
Douglas A; Morris J
Age Ageing; 2006 Nov; 35(6):640-1. PubMed ID: 16943262
[TBL] [Abstract][Full Text] [Related]
15. Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system.
González-Quevedo A; García JC; Fernández R; Fernández Cartaya L
Bol Estud Med Biol; 1993; 41(1-4):13-9. PubMed ID: 7521168
[TBL] [Abstract][Full Text] [Related]
16. Case of neuroleptic malignant-like syndrome precipitated by abrupt fava bean discontinuance.
Ladha SS; Walker R; Shill HA
Mov Disord; 2005 May; 20(5):630-1. PubMed ID: 15719433
[TBL] [Abstract][Full Text] [Related]
17. Neuroleptic malignant-like syndrome with a slight elevation of creatine-kinase levels and respiratory failure in a patient with Parkinson's disease.
Wei L; Chen Y
Patient Prefer Adherence; 2014; 8():271-3. PubMed ID: 24600209
[TBL] [Abstract][Full Text] [Related]
18. Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group.
LeWitt PA; Galloway MP; Matson W; Milbury P; McDermott M; Srivastava DK; Oakes D
Neurology; 1992 Nov; 42(11):2111-7. PubMed ID: 1436520
[TBL] [Abstract][Full Text] [Related]
19. Biochemical aids in the diagnosis of Parkinson's disease.
Chase TN; Eng N; Gordon EK
Ann Clin Lab Sci; 1976; 6(1):4-10. PubMed ID: 1247283
[TBL] [Abstract][Full Text] [Related]
20. Fulminant neuroleptic malignant syndrome after perioperative withdrawal of antiParkinsonian medication.
Stotz M; Thümmler D; Schürch M; Renggli JC; Urwyler A; Pargger H
Br J Anaesth; 2004 Dec; 93(6):868-71. PubMed ID: 15377584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
